Opinion: Why Life Insurers' Rejection of Active Surveillance for Prostate Cancer Misses the Mark

A patient advocates against insurance companies classifying prostate cancer under active surveillance as 'untreated cancer,' arguing that close monitoring by oncologists represents legitimate medical management. Active surveillance is an established clinical approach for low-risk prostate cancer that avoids unnecessary aggressive treatments while maintaining vigilant oversight. Insurance companies' mischaracterization of this evidence-based strategy may unfairly penalize patients and limit access to appropriate care. This issue highlights the growing tension between medical standards of care and insurance industry practices in cancer management.